post-cal color trend
color medic cost trend key take-away earn call
follow unh beat rais provid key takeaway earn
call morn first given unh came better expect
compani provid color us follow-up call trend cost categori
context overal commerci medic cost line
compani expect earli point full year seem flu lead
slight uptick physician pharmaci outpati cost within unh medicaid
commerci book busi flu also led slight uptick inpati cost
medicar book clear much flu-rel util alreadi bake
compani guidanc thu reach level alter outlook medic
cost investor fear inde manag care stock
today hospit stock under-perform and/or back
result higher medic cost thesi may unwind ahead earn
rest sector payor provid side
remind guid inpati cost y-o-i
outpati cost physician cost pharmaci
continu believ may upsid relat pharmaci trend particular
given view well major pbm net pharmaci spend trend may
much lower due primarili brand rx rebat trend
optum key takeaway optum strong ebit growth driven improv
margin due increas product specif subsector optumrx pbm
script growth current script guidanc
larg due client membership expans better mix mail/specialti rx
importantli rx upsid seemingli relat spike util therebi
suggest pharmaci cost trend overal may still track upsid
rais ep high end new guidanc
rang ep pt base price-to-earnings unchang
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight price target
base price-to-earnings
ep street believ
deserv slight premium two mco
coverag due slightli faster ep growth
stem part optum franchis also
upsid case base higher price-to-earnings
higher ep forecast compani
medicar membership growth optum accret
downsid case base lower price-to-earnings
lower ep compani underachiev
medicar growth prospect
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
 quarterli incom statement compani compani compani medic loss ratio product product profit total cost ex-stock comp expens includ incom intang amort pre-tax rate minor interest net incom exclud check ep fulli dilut share barclay
 compani unit healthcar part bn employ targetsoptumhealth consum miloptuminsight biloptumrx adj bnebit target medic bpsoper cost mil ebit reduct due premium chang due mil ebit reduct due premium chang due taxminor mil mil yr/yrdebt/tot cap lt ltmarket ratemarket rate barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
